KOGENATE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY, AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS

被引：0
|
作者：
LUSHER, J
ARKIN, S
ABILDGAARD, CF
HURST, D
机构：
[1] WASHINGTON STATE UNIV,KOGENATE PUP STUDY GRP,PULLMAN,WA 99164
[2] MILES INC,BERKELEY,CA
[3] CUNY MT SINAI SCH MED,NEW YORK,NY 10029
[4] UNIV CALIF DAVIS,DAVIS,CA 95616
来源：
BLOOD | 1994年 / 84卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A239 / A239
页数：1
相关论文
共 50 条
  • [1] RECOMBINANT FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    HURST, D
    PEDIATRIC RESEARCH, 1995, 37 (04) : A161 - A161
  • [2] RECOMBINANT-FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY, AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
    LUSHER, J
    ARKIN, S
    ABILDGAARD, CF
    HURST, D
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1012 - 1012
  • [3] Kogenate treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy, and inhibitor development after seven study years.
    Lusher, J
    Arkin, S
    Abildgaard, CF
    Hurst, D
    BLOOD, 1996, 88 (10) : 1755 - 1755
  • [4] Recombinant FVII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years
    Lusher, J
    Arkin, S
    Abildgaard, CF
    Hurst, A
    THROMBOSIS AND HAEMOSTASIS, 1997, : PD664 - PD664
  • [5] Safety and efficacy of KOGENATE® Bayer in previously untreated patients (PUPS) and minimally treated patients (MTPs)
    Giangrande, PLF
    HAEMOPHILIA, 2002, 8 : 19 - 22
  • [6] RECOMBINANT FACTOR-VIII FOR THE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-A - SAFETY, EFFICACY, AND DEVELOPMENT OF INHIBITORS
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    SCHWARTZ, RS
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (07): : 453 - 459
  • [7] SAFETY, EFFICACY AND INHIBITOR RISK OF RECOMBINANT FACTOR-VIII (RECOMBINATE(R)) IN A COHORT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HEMOPHILIA-A
    BRAY, GL
    COURTER, S
    LYNES, M
    LEE, M
    GOMPERTS, E
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1205 - 1205
  • [8] INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA RECEIVING KOGENATE - 4.5 YEAR FOLLOW-UP DATA, INCLUDING RESPONSE TO IMMUNE TOLERANCE (IT) WITH KOGENATE
    LUSHER, J
    ARKIN, S
    ABILDGAARD, C
    INWOOD, M
    HILGARTNER, M
    HURST, D
    PEDIATRIC RESEARCH, 1994, 35 (04) : A165 - A165
  • [9] CD-4 COUNTS IN HIV-NEGATIVE PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A RECEIVING RECOMBINANT FVIII (KOGENATE)
    WARRIER, I
    ARKIN, S
    ABILDGAARD, C
    TENGBOM, L
    ZIMMERMANN, R
    HURST, D
    BLOOD, 1993, 82 (10) : A601 - A601
  • [10] A MULTICENTER STUDY OF RECOMBINANT FACTOR-VIII (RECOMBINATE) - SAFETY, EFFICACY, AND INHIBITOR RISK IN PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-A
    BRAY, GL
    GOMPERTS, ED
    COURTER, S
    GRUPPO, R
    GORDON, EM
    MANCOJOHNSON, M
    SHAPIRO, A
    SCHEIBEL, E
    WHITE, G
    LEE, M
    GORDON, M
    BERTALONE, S
    LIPTON, R
    HILGARTNER, M
    ARKIN, S
    GILL, J
    KIM, H
    SHURIN, S
    SANTIAGOBORRERO, P
    ARKEL, YS
    KULKARNI, R
    GREENWOOD, MF
    RITCHEY, AK
    WERNER, E
    HAIRE, WD
    KISKER, T
    NEUFELD, E
    EWENSTEIN, B
    DEBIASI, R
    LAURIAN, Y
    KREUZ, W
    RODEGHIERO, F
    INGERSLEV, J
    GAZENGEL, C
    DIMICHELE, D
    COOPER, H
    BLOOD, 1994, 83 (09) : 2428 - 2435
12345